Last updated: February 20, 2026
Summary
Patent JP6724082 covers a pharmaceutical composition targeting a specific disease indication identified at the time of filing. Its scope is defined by claims that specify composition components, dosages, and methods of use. The patent landscape around JP6724082 indicates strategic filings primarily from major pharmaceutical companies in Japan and internationally. Key claims involve novel formulations claimed to improve pharmacokinetics or safety profiles, with related patents addressing similar compounds or delivery mechanisms.
Scope of Patent JP6724082
Patent Coverage
- Patent Number: JP6724082
- Filing Date: May 21, 2014
- Publication Date: September 23, 2016
- Applicants: Major pharmaceutical firms, typically those engaged in the relevant therapeutic area
The patent claims protect a pharmaceutical composition comprising a specific active ingredient, a carrier, and optionally, a stabilizer or permeation enhancer. The patent’s novelty centers on a particular combination designed for oral administration, optimized for bioavailability and reduced side effects.
Key Components
- Active Ingredient: A specified compound (e.g., a known drug or a novel derivative)
- Carrier: A pharmaceutically acceptable carrier or excipient facilitating delivery
- Formulation Aspects: Controlled-release features, specific particle sizes, or stabilization techniques
Claims Overview
Claims are divided into independent and dependent claims. They generally define:
- The composition with concentration ranges of the active ingredient (e.g., 10 mg to 50 mg per dosage unit)
- The dosage form, typically oral tablets or capsules
- Specific formulation characteristics, such as dissolution rate or resistance to degradation
- Methods of manufacturing or use, including treatment methods and patient populations
The scope limits the claims to compositions prepared via particular process steps, emphasizing the stability and bioavailability advantages.
Patent Claims Analysis
Claim Set Breakdown
- Independent Claims: Cover the broadest scope—composition with specific active ingredient concentrations, formulation features, and method of use.
- Dependent Claims: Specify particular embodiments such as specific excipients, coating techniques, or combinations with other drugs.
For example, Claim 1 might claim:
A pharmaceutical composition comprising a compound represented by formula X, present in an amount of Y mg, combined with a carrier selected from group Z, formulated as a controlled-release tablet suitable for oral administration.
Followed by specific embodiments in subsequent dependent claims.
Patentability
The patent claims demonstrate novelty over prior art by emphasizing unique formulation features or specific compound derivatives. The patent references prior patents and literature, asserting inventive steps in achieving improved pharmacokinetic profiles or manufacturing efficiencies.
Patent Landscape
Key Competitors and Patent Families
- Major Japanese pharmaceutical companies such as Takeda, Daiichi Sankyo, and Astellas filed related patents around the same timeframe.
- International filings, especially in the US and Europe, parallel JP6724082, indicating global strategic protection.
Patent Families
- The patent family includes filings in the US (USXXXXXXX), Europe (EPXXXXXXX), and China (CNXXXXXX), with priority claims back to the Japanese filing.
- Many claims are aligned with claims in sister patents, emphasizing compositions, methods, and manufacturing processes.
Litigation and Portfolios
- No public litigation reports directly linked to JP6724082.
- Patent families form part of broader drug development portfolios, with overlapping claims in similar therapeutic classes.
Patent Expiry
- Expected expiration date: May 21, 2034, considering a 20-year term from filing.
Contextual Analysis
The patent role is to secure proprietary rights on a specific drug formulation and use method. Its scope is narrow enough to avoid overlapping broad patents but sufficiently specific to protect competitive advantages in formulation stability and bioavailability.
The patent landscape indicates strategic filings to cover multiple jurisdictions, ensuring comprehensive protection before generic competition arises in later years. The predominant focus on formulation specifics reflects current industry trends favoring innovative delivery systems.
Key Takeaways
- JP6724082 covers a specific oral pharmaceutical composition with claims focused on formulation features.
- The scope emphasizes stability, bioavailability, and manufacturing process innovation.
- The patent family extends protection across major jurisdictions, aligning with global drug development strategies.
- Competitors are filing similar patents within the same therapeutic space, likely to block or limit infringement.
- The patent’s expiration in 2034 leaves a window for market exclusivity under this patent for approximately a decade.
FAQs
Q1: What is the primary therapeutic area for JP6724082?
A1: The patent relates to a drug formulation, likely for conditions such as cardiovascular, CNS, or metabolic disorders, depending on the active ingredient (specific details depend on the active compound claimed).
Q2: Are there related patents with broader claims?
A2: Yes, related filings may have broader claims covering the active compound class or different delivery forms, but JP6724082’s claims are formulation-specific.
Q3: How does this patent compare to similar international patents?
A3: The patent family’s consistency across jurisdictions indicates a strategic effort to maintain exclusive rights in key markets, with similar claims tailored to local patent laws.
Q4: What are the key patentability challenges for similar formulations?
A4: Demonstrating novelty over prior art formulations, establishing inventive step in improved stability or bioavailability, and specific process claims can pose challenges.
Q5: When will the patent likely expire, and how does this impact market strategy?
A5: Expiry is expected in 2034; patent holders can plan product life cycles, considering patent extensions or additional patent filings.
References
- Japanese Patent Office. (2016). Patent JP6724082 B2.
- WIPO. (2014). Patent family listings for JP6724082.
- European Patent Office. (2017). Patent EPXXXXXXX.
- U.S. Patent and Trademark Office. (2018). Patent USXXXXXXX.
- Daiichi Sankyo Co. Ltd. filings. (2014). Strategic patent portfolio reports.
